Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV- mutated chronic lymphocytic leukemia

Philip A. Thompson, Constantine S. Tam, Susan M. O’Brien, William G. Wierda, Francesco Stingo, William Plunkett, Susan C. Smith, Hagop M. Kantarjian, Emil J. Freireich, Michael J. Keating

Blood (2016) 127 (3): 303–309.

https://doi.org/10.1182/blood-2015-09-667675

Published: 2016

Includes: Supplemental data

Journal Articles

Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens

Philip A Thompson, MBBS, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Susan C. Smith, Susan O'Brien, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Nitin Jain, MD, Hagop M. Kantarjian, MD, Michael J Keating, MBBS

Blood (2014) 124 (21): 22.

https://doi.org/10.1182/blood.V124.21.22.22

Published: 2014

Journal Articles

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Philip A Thompson, Michael J Keating, MBBS, Christina Hinojosa, Susan C. Smith, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Susan O'Brien, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD

Blood (2014) 124 (21): 1988.

https://doi.org/10.1182/blood.V124.21.1988.1988

Published: 2014

Journal Articles

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

Lorenzo Falchi, Michael J. Keating, Edith M. Marom, Mylene T. Truong, Ellen J. Schlette, Rachel L. Sargent, Long Trinh, Xuemei Wang, Susan C. Smith, Nitin Jain, Zeev Estrov, Susan O’Brien, William G. Wierda, Susan Lerner, Alessandra Ferrajoli

Blood (2014) 123 (18): 2783–2790.

https://doi.org/10.1182/blood-2013-11-536169

Published: 2014

Journal Articles

Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

Paolo Strati, MD, Michael J. Keating, MD, Christina Hinojosa, Stefan Faderl, MD, Susan C. Smith, Susan O'Brien, MD, Jan A. Burger, MD, PhD, William G. Wierda, MD, Alessandra Ferrajoli, MD

Blood (2013) 122 (21): 4183.

https://doi.org/10.1182/blood.V122.21.4183.4183

Published: 2013

Journal Articles

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Lorenzo Falchi, MD, Long Xuan Trinh, Edith M. Marom, MD, Mylene Truong, MD, Ellen Schlette, MD, Rachel L. Sargent, MD, Xuemei Wang, MS, Susan C. Smith, Susan Lerner, MS, Michael J. Keating, MD, Alessandra Ferrajoli, MD

Blood (2012) 120 (21): 927.

https://doi.org/10.1182/blood.V120.21.927.927

Published: 2012

Journal Articles

Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Alessandra Ferrajoli, M.D., Lorenzo Falchi, MD, Susan O'Brien, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Susan C. Smith, BS, Ana B. Ayala, ADN, Hagop M. Kantarjian, MD, Michael J. Keating, MD

Blood (2012) 120 (21): 720.

https://doi.org/10.1182/blood.V120.21.720.720

Published: 2012

Journal Articles

Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Alessandra Ferrajoli, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Xavier Badoux, MD, Zeev Estrov, Ellen Schlette, MD, Susan C. Smith, BS, Ana B. Ayala, ADN, Lorenzo Falchi, MD, Steliana Calin, MD, Hagop M. Kantarjian, MD, Michael J Keating, MD

Blood (2011) 118 (21): 1788.

https://doi.org/10.1182/blood.V118.21.1788.1788

Published: 2011

Journal Articles

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Issa Khouri, MD, BS, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Sijin Wen, MS, Susan C. Smith, BS, Susan Lerner, MS, BA, Emil J. Freireich, MD, BS, Michael J. Keating, MD

Blood (2005) 106 (11): 2097.

https://doi.org/10.1182/blood.V106.11.2097.2097

Published: 2005

Journal Articles

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

Raphaël F. Rousseau, Ann E. Haight, Charlotte Hirschmann-Jax, Eric S. Yvon, Donna R. Rill, Zhuyong Mei, Susan C. Smith, Shannon Inman, Kristine Cooper, Pat Alcoser, Bambi Grilley, Adrian Gee, Edwina Popek, Andrew Davidoff, Laura C. Bowman, Malcolm K. Brenner, Douglas Strother

Blood (2003) 101 (5): 1718–1726.

https://doi.org/10.1182/blood-2002-08-2493

Published: 2003

NARROW

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV- mutated chronic lymphocytic leukemia

Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only